A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?

Neil S. Maitra, Dhruv Mahtta, Sankar Navaneethan, Elizabeth M. Vaughan, Ajar Kochar, Martha Gulati, Glenn N. Levine, Laura A. Petersen, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Purpose of Review: To review the factors contributing to underutilization of guideline-directed therapies, identify strategies to alleviate these factors, and apply these strategies for effective and timely dissemination of novel cardioprotective glucose-lowering agents. Recent Findings: Recent analyses demonstrate underutilization of cardioprotective glucose lowering agents despite guideline recommendations for their use. Major contributors to underutilization of guideline-directed therapies include therapeutic inertia, perceptions about side effects, and factors found at the level of the clinicians, patients, and the healthcare system. Summary: The recent emergence of several novel therapies, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, for use in cardiovascular disease provides a unique avenue to improve patient outcomes. To effectively utilize novel cardioprotective glucose lowering agents to improve cardiovascular outcomes, clinicians must recognize and learn from prior barriers to application of guideline-directed therapies. Further endeavors are prudent to ensure uptake of novel agents.

Original languageEnglish (US)
Pages (from-to)689-698
Number of pages10
JournalCurrent Cardiology Reports
Volume24
Issue number6
DOIs
StatePublished - Jun 2022
Externally publishedYes

Keywords

  • Glucose-lowering agents
  • Statins
  • Therapeutic inertia
  • Utilization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?'. Together they form a unique fingerprint.

Cite this